Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;121(5):737-744.
doi: 10.1111/bju.14106. Epub 2018 Jan 18.

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

Sophie M Bruinsma  1 , Liying Zhang  2 , Monique J Roobol  1 , Chris H Bangma  1 , Ewout W Steyerberg  3 , Daan Nieboer  1   3 , Mieke Van Hemelrijck  4 ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Collaborators, Affiliations
Free article

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

Sophie M Bruinsma et al. BJU Int. 2018 May.
Free article

Abstract

Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database.

Patients and methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time.

Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing.

Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

Keywords: #PCSM; #ProstateCancer; adenocarcinoma; evidence-based; guideline.

PubMed Disclaimer

Publication types